Mifepristone priming and subsequent misoprostol for second trimester medical abortion in women with previous caesarean delivery

被引:4
|
作者
Dickinson, Jan E. [1 ,3 ]
Doherty, Dorota A. [2 ]
机构
[1] Univ Western Australia, Div Obstet & Gynaecol, Maternal Fetal Med, Perth, WA, Australia
[2] Univ Western Australia, Div Obstet & Gynaecol, Biostat & Res Design Unit, Perth, WA, Australia
[3] Univ Western Australia, King Edward Mem Hosp, Div Obstet & Gynaecol, 374 Bagot Rd, Subiaco, WA 6008, Australia
关键词
caesarean section; medical abortion; mifepristone; misoprostol; second trimester; uterine rupture; PREGNANCY TERMINATION; VAGINAL MISOPROSTOL;
D O I
10.1111/ajo.13653
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Aims: To assess clinical outcomes and complications in women with >= 1 prior caesarean delivery (CS) during mid-pregnancy medical abortion with misoprostol following mifepristone priming. Materials and Methods: Retrospective analysis of abortions at 13-28 weeks gestation using sequential mifepristone and misoprostol at a single centre from 1/2008-12/2018. Procedural outcomes were compared between cases with no prior CS, one prior and >= 2 prior CS. Results: There were 1399 consecutive women who underwent a medical abortion, with 304 (21.7%) having >= 1 prior lower segment CS (241 one, 49 two, 12 three, one four) and one a prior classical CS. Median gestation was 19 weeks (interquartile range (IQR) 17-21) among nulliparas, multiparas with no prior CS and multiparas with prior CS, P = 0.505. Compared with nulliparas (median procedural duration 10.8 h, IQR 7.5-16.5; adjusted hazards ratio (aHR) = 1.20 95%CI 1.04-1.40, P = 0.015), multiparas with prior CS had a shorter procedural duration (9.5 h, IQR 6.5-13.5) while multiparas with no CS had the shortest duration (7.0 h, IQR 5.0-9.8; aHR = 2.28 95%CI 2.01-2.58, P < 0.001). Complications were more frequent with prior CS: estimated blood loss (medians: 100 cc no CS vs 150 cc >= 1 CS, P = 0.002), blood loss >1000 cc (3.6% no CS vs 7.2% >= 1 CS; odds ratio (OR) >= 2.11 95%CI 1.23-3.62, P = 0.007) and placental retention (17.3% no CS vs 25.3% >= 1 CS; adjusted OR = 1.44 95%CI 1.05-1.99, P = 0.024). Uterine rupture occurred in 4/304 women with >= 1 prior CS (1.3%). Conclusions: Mifepristone-misoprostol abortion in women with prior CS is generally safe but associated with an increased risk of procedural complications. Lowering of the misoprostol dosage with prior CS may reduce uterine rupture, although this hypothesis requires ongoing research.
引用
收藏
页码:301 / 307
页数:7
相关论文
共 50 条
  • [1] Maternal complications associated with second trimester medical abortion using mifepristone priming and subsequent misoprostol
    Dickinson, Jan E.
    Doherty, Dorota A.
    CONTRACEPTION, 2023, 125
  • [2] Mifepristone-misoprostol second trimester medical termination in women with previous cesarean delivery
    Dickinson, Jan Elizabeth
    Doherty, Dorota A.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2017, 216 (01) : S495 - S495
  • [4] Misoprostol priming prior to second trimester medical abortion
    Moreno-Ruiz, Nilda L.
    Vesona, Jenny L.
    Betstadt, Sarah J.
    Feng, Kui-Tzu
    Borgatta, Lynn
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2009, 106 (01) : 67 - 68
  • [5] Investigation of a variable mifepristone to misoprostol interval for second trimester medical abortion
    Henkel, A.
    Lerma, K.
    Blumenthal, P. D.
    Shaw, K. A.
    CONTRACEPTION, 2018, 97 (05) : 462 - 462
  • [6] Second Trimester Medical Abortion with Mifepristone-Misoprostol and Misoprostol Alone: A Review of Methods and Management
    Gewell-Danielsson, Kristina
    Lalitkumar, Sujata
    REPRODUCTIVE HEALTH MATTERS, 2008, 16 (31) : 162 - 172
  • [7] Mifepristone and Misoprostol Compared With Misoprostol Alone for Second-Trimester Abortion
    Nguyen Thi Nhu Ngoc
    Shochet, Tara
    Raghavan, Sheila
    Blum, Jennifer
    Nguyen Thi Bach Nga
    Nguyen Thi Hong Minh
    Van Quy Phan
    Winikoff, Beverly
    OBSTETRICS AND GYNECOLOGY, 2011, 118 (03): : 601 - 608
  • [8] Second trimester medical abortion with mifepristone followed by unlimited dosing of buccal misoprostol in Armenia
    Louie, Karmen S.
    Chong, Erica
    Tsereteli, Tamar
    Avagyan, Gayane
    Abrahamyan, Ruzanna
    Winikoff, Beverly
    EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2017, 22 (01): : 76 - 80
  • [9] Efficacy and safety of mifepristone and sublingual misoprostol for second trimester medical abortion. A prospective study
    Peitsidis, N.
    Kapetanios, G.
    Kalogiannidis, I.
    Tsakiridis, I.
    Virgiliou, A.
    Dagklis, T.
    Mamopoulos, A.
    Athanasiadis, A.
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2022, 270 : E97 - E97
  • [10] Evaluation of shorter mifepristone to misoprostol intervals for second trimester medical abortion: a retrospective cohort study
    Henkel, Andrea
    Lerma, Klaira
    Blumenthal, Paul D.
    Shaw, Kate A.
    CONTRACEPTION, 2020, 102 (05) : 327 - 331